|
Secondary Neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
BIRC5/Survivin is known as a dual cellular functions protein that directly regulates both apoptosis and mitosis in embryonic cells during embryogenesis and in cancer cells during tumorigenesis and tumor metastasis.
|
31612776 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
|
17087938 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A role of apoptosis (programmed cell death) in tumor formation and growth was investigated by targeting the apoptosis inhibitor survivin in vivo.
|
11149963 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A total of 42 osteosarcoma patients were collected for tumor and adjacent tissues to compare miR-218 and BIRC5 expressions.
|
30402837 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aberrant expression of baculoviral IAP repeat containing 5 (BIRC5) is associated with the tumor growth and metastasis, however, the clinical significance of miRNAs/BIRC5 axis in gastric cancer (GC) remains unknown.
|
31663299 |
2019 |
|
Neoplasm Metastasis
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Aberrant expression of baculoviral IAP repeat containing 5 (BIRC5) is associated with the tumor growth and metastasis, however, the clinical significance of miRNAs/BIRC5 axis in gastric cancer (GC) remains unknown.
|
31663299 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Abnormal expression of Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5, also called as survivin), a novel member of the inhibitor of apoptosis protein (IAP) family, has implications in many types of cancer and is considered as a new therapeutic target.
|
23883402 |
2013 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Abnormal expression of Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5, also called as survivin), a novel member of the inhibitor of apoptosis protein (IAP) family, has implications in many types of cancer and is considered as a new therapeutic target.
|
23883402 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, plasmid-based siRNA against Birc5 and/or Hspa5 were constructed and transfected into the human hepatocellular liver carcinoma cell line, HepG2.
|
22581315 |
2012 |
|
Mammary Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.
|
18451232 |
2008 |
|
Neurofibromatosis 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
Among the genes mapping to this region, BIRC5, which encodes the baculoviral IAP repeat-containing protein 5/survivin protein, is a strong candidate target gene for amplification, as it has been previously shown to be overexpressed in neurofibromatosis type 1-associated MPNST.
|
16721726 |
2006 |
|
Malignant Peripheral Nerve Sheath Tumor
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Among the genes mapping to this region, BIRC5, which encodes the baculoviral IAP repeat-containing protein 5/survivin protein, is a strong candidate target gene for amplification, as it has been previously shown to be overexpressed in neurofibromatosis type 1-associated MPNST.
|
16721726 |
2006 |
|
Gastrointestinal Stromal Tumors
|
0.020 |
Biomarker
|
group |
BEFREE |
Amplification of the respective gene loci (BIRC2, BIRC3, BIRC4, BIRC5) was detected in 47% of GIST studied by SNP arrays.
|
27167336 |
2016 |
|
ovarian neoplasm
|
0.370 |
Biomarker
|
disease |
BEFREE |
An increasing number of studies have confirmed that survivin (BIRC5) plays essential roles in ovarian cancer.
|
29499854 |
2018 |
|
Malignant neoplasm of ovary
|
0.330 |
Biomarker
|
disease |
BEFREE |
An increasing number of studies have confirmed that survivin (BIRC5) plays essential roles in ovarian cancer.
|
29499854 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.030 |
Biomarker
|
disease |
BEFREE |
An increasing number of studies have confirmed that survivin (BIRC5) plays essential roles in ovarian cancer.
|
29499854 |
2018 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An upgrade risk in rs9904341 of BIRC5 were revealed to be associated with urinary cancer in allele contrast model (OR = 1.222, P = 0.012), homozygote contrast model (OR = 1.579, P = 0.0001) and recessive contrast model (OR = 1.433, P < 0.001), as well as rs2071214 polymorphism in the subgroup analysis of BCa in allele contrast model (OR = 1.362, P = 0.011) and recessive contrast model (OR = 1.417, P = 0.015).
|
31809840 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An upgrade risk in rs9904341 of BIRC5 were revealed to be associated with urinary cancer in allele contrast model (OR = 1.222, P = 0.012), homozygote contrast model (OR = 1.579, P = 0.0001) and recessive contrast model (OR = 1.433, P < 0.001), as well as rs2071214 polymorphism in the subgroup analysis of BCa in allele contrast model (OR = 1.362, P = 0.011) and recessive contrast model (OR = 1.417, P = 0.015).
|
31809840 |
2020 |
|
Infection
|
0.040 |
AlteredExpression
|
group |
LHGDN |
Analyses of Bcl-2, Survivin, and CD44v6 expressions and human papillomavirus infection in cervical carcinomas.
|
17464868 |
2007 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
RGD |
Angiogenic signal triggered by ischemic stress induces myocardial repair in rat during chronic infarction.
|
15081314 |
2004 |
|
leukemia
|
0.040 |
Biomarker
|
disease |
LHGDN |
Antisense RNA of survivin gene inhibits the proliferation of leukemia cells and sensitizes leukemia cell line to taxol-induced apoptosis.
|
18278445 |
2008 |
|
Bladder Neoplasm
|
0.060 |
Biomarker
|
disease |
LHGDN |
Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.
|
18425331 |
2008 |
|
Prostatic Neoplasms
|
0.340 |
Biomarker
|
group |
CTD_human |
APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells.
|
29541389 |
2018 |
|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
CTD_human |
APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells.
|
29541389 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a mitotic spindle checkpoint gene, baculoviral IAP repeat containing 5 (BIRC5) serves pivotal roles in the development of various types of malignant tumors.
|
30127937 |
2018 |